4D Molecular Therapeutics, Inc. (FDMT) vs Starling Oncology, Inc. (STLN)
A side-by-side comparison of 4D Molecular Therapeutics, Inc. and Starling Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FDMT
4D Molecular Therapeutics, Inc.
$12.85HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
STLN
Starling Oncology, Inc.
$6.56HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
Total return — FDMT vs STLN
growth of $100 · dividends reinvested · last 1yFDMT +1.6% (+1.6%/yr)STLN +8.6% (+8.6%/yr)STLN compounded faster over this window
FDMT STLN
FDMT vs STLN: by the numbers
- •FDMT is the larger company ($672M vs $656M market cap).
- •Both run net losses; STLN's is the smaller (-6.18% vs -194.74% net margin).
Metrics side by side
Valuation
| Metric | FDMT | STLN |
|---|---|---|
| P/S ratio | 7.30 | 1.12 |
| P/B ratio | 1.65 | N/A |
Profitability
| Metric | FDMT | STLN |
|---|---|---|
| Gross margin | 91.05% | 15.69% |
| Operating margin | -187.24% | -4.44% |
| Net margin | -194.74% | -6.18% |
| ROE | -43.95% | N/A |
| ROIC | -44.30% | -31.32% |
Growth (annualized)
| Metric | FDMT | STLN |
|---|---|---|
| Revenue CAGR (5Y) | 31.93% | N/A |
| Total return CAGR (5Y) | -13.08% | N/A |
Go deeper
Dig into the metrics
4D Molecular Therapeutics ROEStarling Oncology ROE4D Molecular Therapeutics operating marginStarling Oncology operating margin4D Molecular Therapeutics revenue growthStarling Oncology revenue growth4D Molecular Therapeutics free cash flowStarling Oncology free cash flow
4D Molecular Therapeutics & Starling Oncology appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.